Are you eating too much fiber? - Harvard Health

If you have Type 2 diabetes, you’ve probably spent plenty of time thinking about what to eat to help keep your blood sugar (glucose) steady. But did you know that the order in which you eat different foods can help, too? When it comes to meal order, fiber deserves first place. Registered dietitian Tegan Bissell, RD, LDN, CDCES, explains the benefits of dietary fiber and how eating it first can help keep your post-meal glucose in range. Fiber and its role in diabetesMost people think of fiber as the nutrient that helps keep you regular. But it also has many other health benefits, especially when you have diabetes. One of dietary fiber’s biggest benefits is its role in blood sugar management. Fiber is a type of carbohydrate, but it works differently from typical carbs. Your body can’t break it down, which means it doesn’t raise blood glucose the same way other carbs do. So, eating high-fiber foods can slow digestion. “When you eat fiber with a meal, sugar reaches your bloodstream in a more controlled manner, preventing blood sugar spikes,” explains Bissell.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.